Enanta Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
AbbVie USD 62.48B 2.05B Jun/2026
Amgen USD 51.61B 250M Sep/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
AstraZeneca USD 28.8B 2.79B Sep/2026
BioCryst Pharmaceuticals USD 395.61M 209K Sep/2026
Biogen USD 7.29B 1.7M Sep/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 23.82B 17M Sep/2026
GlaxoSmithKline GBP 21.7B 7.75B Sep/2026
Halozyme Therapeutics USD 2.94B 1.01B Sep/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Immunic USD 0 0 Jun/2024
Incyte USD 28.42M 994K Jun/2026
Insmed USD 544.86M 1.35M Sep/2026
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
J&J USD 35.8B 1.55B Sep/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
Ligand Pharmaceuticals USD 1.13B 679.7M Jun/2026
Merck USD 49.69B 1.39B Sep/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 38.38B 893M Sep/2026
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60B 498M Sep/2026
PTC Therapeutics USD 536.27M 749K Sep/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026